Statement re Injectables Pres

RNS Number : 8400I

Hikma Pharmaceuticals Plc

25 November 2008

 



Hikma Pharmaceuticals PLC - Injectables Presentation

LONDON, 25 November 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) the fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of generic and in-licensed pharmaceutical products will today present to investors and analysts on the company's Global Injectables business. A copy of this presentation and an audio replay will be available on the company's website at www.hikma.com.

The company will also be attending the HSBC European Healthcare Conference in London on the 26th of November. A copy of this presentation will also be available on the company's website.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC
Susan Ringdal Investor Relations Director	[phone]
Brunswick
Jon Coles/Justine McIlroy	[phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: 'Branded', 'Injectables' and 'Generics'. Hikma's operations are based principally in the Middle East and North Africa ('MENA') region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2007, the Group achieved revenues of $449 million and profit attributable to shareholders was $63 million. For news and other information, please visit www.hikma.com.

 

END

 

 

STRMGMZMGDNGRZZ